Literature DB >> 10520935

Molecular pathogenesis of Friedreich ataxia.

M Pandolfo1.   

Abstract

Friedreich ataxia, the most common type of inherited ataxia, is itself caused in most cases by a large expansion of an intronic GAA repeat, resulting in decreased expression of the target frataxin gene. The autosomal recessive inheritance of the disease gives this triplet repeat mutation some unique features of natural history and evolution. Frataxin is a mitochondrial protein that has homologues in yeast and even in gram-negative bacteria. Yeast organisms deficient in the frataxin homologue accumulate iron in mitochondria and show increased sensitivity to oxidative stress. This suggests that Friedreich ataxia is caused by mitochondrial dysfunction and free radical toxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520935     DOI: 10.1001/archneur.56.10.1201

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  24 in total

Review 1.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

2.  Replication stalling at Friedreich's ataxia (GAA)n repeats in vivo.

Authors:  Maria M Krasilnikova; Sergei M Mirkin
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 3.  How Is Fe-S Cluster Formation Regulated?

Authors:  Erin L Mettert; Patricia J Kiley
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

4.  PEP-1-frataxin significantly increases cell proliferation and neuroblast differentiation by reducing lipid peroxidation in the mouse dentate gyrus.

Authors:  Woosuk Kim; Dae Won Kim; Bich Na Shin; Dae Young Yoo; Sung Min Nam; Mi Jin Kim; Jung Hoon Choi; Yeo Sung Yoon; Moo-Ho Won; Soo Young Choi; In Koo Hwang
Journal:  Neurochem Res       Date:  2011-09-01       Impact factor: 3.996

5.  Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia.

Authors:  A O Hausse; Y Aggoun; D Bonnet; D Sidi; A Munnich; A Rötig; P Rustin
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

6.  Analysis of the visual system in Friedreich ataxia.

Authors:  Lauren A Seyer; Kristin Galetta; James Wilson; Reiko Sakai; Susan Perlman; Katherine Mathews; George R Wilmot; Christopher M Gomez; Bernard Ravina; Theresa Zesiewicz; Khalaf O Bushara; S H Subramony; Tetsuo Ashizawa; Martin B Delatycki; Alicia Brocht; Laura J Balcer; David R Lynch
Journal:  J Neurol       Date:  2013-06-18       Impact factor: 4.849

Review 7.  Pharmacotherapy for Friedreich ataxia.

Authors:  Amy Y Tsou; Lisa S Friedman; Robert B Wilson; David R Lynch
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Frataxin gene point mutations in Italian Friedreich ataxia patients.

Authors:  Cinzia Gellera; Barbara Castellotti; Caterina Mariotti; Rossana Mineri; Viviana Seveso; Stefano Didonato; Franco Taroni
Journal:  Neurogenetics       Date:  2007-08-17       Impact factor: 2.660

9.  Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.

Authors:  Lisa S Friedman; Jennifer M Farmer; Susan Perlman; George Wilmot; Christopher M Gomez; Khalaf O Bushara; Katherine D Mathews; S H Subramony; Tetsuo Ashizawa; Laura J Balcer; Robert B Wilson; David R Lynch
Journal:  Mov Disord       Date:  2010-03-15       Impact factor: 10.338

10.  Diagnosis and Genetic Counseling for Friedreich's Ataxia: A time for consideration of TP-PCR in an Indian Setup.

Authors:  S Muthuswamy; S Agarwal; Ar Dalal
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.